Trial watch: Phase III and submission failures: 2007–2010

  title={Trial watch: Phase III and submission failures: 2007–2010},
  author={John Edmund Arrowsmith},
  journal={Nature Reviews Drug Discovery},
  • J. Arrowsmith
  • Published 1 February 2011
  • Medicine
  • Nature Reviews Drug Discovery

Innovación tecnológica y financiación de prestaciones

    La aparición de numerosas y variadas nuevas tecnologías con novedosos mecanismos de acción bajo un patrón de innovación incremental demanda una reforma estructural profunda de la regulación de

Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer

The data suggests that the use of matched low-passage cell lines and patient-derived xenografts is a promising strategy to identify new therapies and pathways to treat metastatic CRC.

Optimal sample size allocation and go/no‐go decision rules for phase II/III programs where several phase III trials are performed

Optimal phase II sample sizes and go/no-go decision rules are provided for time-to-event outcomes and cases, where at least one, two, or three phase III trials need to be successful.

Can animal data translate to innovations necessary for a new era of patient-centred and individualised healthcare? Bias in preclinical animal research

Bias in animal research needs to be addressed before medical research and healthcare decision-making can be more evidence-based and proposals need development through open debate and subsequent rigorous implementation so that reviewers may determine the value of animal research to human health.

The Ethical Implications for Humans in Light of the Poor Predictive Value of Animal Models

Trans-Species Modeling Theory (TSMT) is examined, the empirical evidence surrounding the use of animal models, and the opinions of experts are examined; the ethical implications regarding research constructed to find cures and treatments for humans are discussed.

Why is publication of negative clinical trial data important?

The impact of reducing failure in clinical trials should be greater than reducing failure at all points along the drug discovery and development process, as this is where the most spend occurs.

The Power of Boolean Implication Networks

Human diseases have been investigated in the context of single genes as well as complex networks of genes. Though single gene approaches have been extremely successful in the past, most human